Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer
CLOCC Trial (Chemotherapy + Local Ablation Versus Chemotherapy) Randomized Phase II Study Of Local Treatment Of Liver Metastases By Radiofrequency Combined With Chemotherapy Versus Chemotherapy Alone In Patients With Unresectable Colorectal Liver Metastases
Sponsor: Arbeitsgruppe Lebermetastasen und Tumoren
Terminated
low accrual
Other Colorectal Cancer trials with similar outcome
Listed as NCT00043004, this PHASE2 trial focuses on Colorectal Cancer and Metastatic Cancer and remains terminated or withdrawn. Sponsored by Arbeitsgruppe Lebermetastasen und Tumoren, it has been updated 6 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
May 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Arbeitsgruppe Lebermetastasen und Tumoren
- European Organisation for Research and Treatment of Cancer - EORTC
- Institute of Cancer Research, United Kingdom
For direct contact, visit the study record on ClinicalTrials.gov .